1. Home
  2. CRF vs PCRX Comparison

CRF vs PCRX Comparison

Compare CRF & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cornerstone Total Return Fund Inc. (The)

CRF

Cornerstone Total Return Fund Inc. (The)

N/A

Current Price

$6.10

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

N/A

Current Price

$24.47

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CRF
PCRX
Founded
N/A
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
1997
2010

Fundamental Metrics

Financial Performance
Metric
CRF
PCRX
Price
$6.10
$24.47
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$30.25
AVG Volume (30 Days)
1.6M
418.6K
Earning Date
01-01-0001
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.44
EPS
N/A
0.19
Revenue
N/A
$541,533,000.00
Revenue This Year
N/A
$6.78
Revenue Next Year
N/A
$8.54
P/E Ratio
N/A
$126.21
Revenue Growth
N/A
26.04
52 Week Low
$6.30
$18.80
52 Week High
$8.25
$27.66

Technical Indicators

Market Signals
Indicator
CRF
PCRX
Relative Strength Index (RSI) 26.31 37.70
Support Level N/A $21.97
Resistance Level $7.31 $26.93
Average True Range (ATR) 0.08 0.71
MACD -0.00 -0.18
Stochastic Oscillator 21.28 10.12

Price Performance

Historical Comparison
CRF
PCRX

About CRF Cornerstone Total Return Fund Inc. (The)

Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology, Health Care, Financials, Communication Services, Consumer Discretionary, Industrials, Exchange-Traded Funds, Utilities, Energy, Real Estate, and others.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: